Central monoamine metabolism in man. Effect of putative dopamine receptor agonists and antagonists.
D000328:Adult; D001480:Basal Ganglia Diseases / Q000378:metabolism; D001921:Brain / Q000378:metabolism*; D002493:Central Nervous System Diseases / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism*; D006220:Haloperidol / Q000494:pharmacology*; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006816:Huntington Disease / Q000378:metabolism; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D009135:Muscular Diseases / Q000378:metabolism; D010300:Parkinson Disease / Q000378:metabolism; D010879:Piperazines / Q000494:pharmacology*; D011339:Probenecid / Q000494:pharmacology; D011955:Receptors, Drug; D012701:Serotonin / Q000378:metabolism*
D010879:Piperazines; D011955:Receptors, Drug; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D006220:Haloperidol; D011339:Probenecid; D004298:Dopamine; D006719:Homovanillic Acid